We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EL:NYSEEstee Lauder Companies, Inc. (The) Analysis

Data as of 2026-03-10 - not real-time

$95.61

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

The stock is trading at $95.61, which sits just above the 200‑day SMA of $94.00 but below the 20‑day ($105.43) and 50‑day ($109.19) averages, indicating a short‑term pullback within a longer‑term uptrend. Momentum signals are mixed: the RSI at 36 points to modest oversold pressure, while the MACD line remains bearish at –4.12 versus its signal at –2.37, producing a negative histogram. Volatility is elevated at roughly 75% over the past 30 days and beta clocks in at 1.54, suggesting the share will swing more than the market. Technical support sits near $88.17 and resistance near $117.57, giving the price a $7‑point cushion above the nearest floor. The DCF‑derived fair value of $65.02 places the current price well above intrinsic estimates, yielding an upside/downside metric of +14.7% that reflects overvaluation rather than upside potential. The Fear & Greed Index reads 80.41 (“Extreme Greed”), hinting that market sentiment may be overly bullish.
Recent earnings beat and raised guidance fuel optimism, with Q2 2026 EPS at $0.89 and a Citi upgrade to “Buy.” Conversely, HSBC downgraded the stock to “Hold,” and the dividend payout ratio of 471% of earnings raises questions about sustainability. Revenue is growing at 5.6% YoY with strong gross margins (74%), yet the company posted a negative trailing EPS and a modest ROE of –4.3%, underscoring earnings volatility. With a forward PE of 31.5 and a price‑to‑book of 8.6, the valuation leans heavily on growth expectations rather than current cash generation. Overall, the stock sits at the intersection of solid brand momentum and a stretched valuation, making it a cautious play for investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent earnings beat and raised guidance
  • Bearish MACD and elevated volatility
  • Support level provides downside cushion

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • Price well above DCF fair value
  • High beta and volatility
  • Unsustainable dividend payout

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong brand portfolio and revenue growth
  • Long‑term growth premium embedded in valuation
  • Potential for valuation correction

Key Metrics & Analysis

Financial Health

Revenue Growth5.60%
Profit Margin-1.21%
P/E Ratio31.5
ROE-4.34%
ROA4.42%
Debt/Equity232.94
P/B Ratio8.6
Op. Cash Flow$1.7B
Free Cash Flow$1.7B

Technical Analysis

TrendNeutral
RSI36.0
Support$88.17
Resistance$117.57
MA 20$105.43
MA 50$109.19
MA 200$94.00
MACDBearish
VolumeStable
Fear & Greed Index80.41

Valuation

Fair Value$65.02
Target Price$109.70
Upside/Downside14.73%
GradeOvervalued
TypeGrowth
Dividend Yield1.51%

Risk Assessment

Beta1.54
Volatility74.85%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.